Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Dimerix Limited ( (AU:DXB) ).
Dimerix Limited has successfully recruited its first pediatric patient for the ACTION3 Phase 3 clinical trial aimed at treating FSGS in children aged 12-17. This milestone supports potential marketing approval for DMX-200 in this age group, with recruitment spanning 19 specialist sites across four countries. The trial’s positive progression could expand DMX-200’s approval to pediatric patients in key territories, including the US and Europe, aligning with FDA and EMA expectations.
More about Dimerix Limited
Dimerix Limited is a biopharmaceutical company specializing in developing treatments for kidney diseases. The company is focused on advancing its Phase 3 clinical asset, DMX-200, for treating focal segmental glomerulosclerosis (FSGS), a leading cause of kidney failure in children.
YTD Price Performance: 45.59%
Average Trading Volume: 2,097,252
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: A$276.2M
See more insights into DXB stock on TipRanks’ Stock Analysis page.